Shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) have been assigned an average recommendation of "Hold" from the thirteen analysts that are currently covering the company, MarketBeat Ratings reports. Ten research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $649.27.
MEDP has been the topic of a number of analyst reports. Robert W. Baird set a $699.00 price objective on shares of Medpace in a research note on Friday, October 23rd. Jefferies Financial Group restated a "hold" rating on shares of Medpace in a research report on Monday, September 14th. Royal Bank Of Canada boosted their target price on shares of Medpace from $484.00 to $692.00 and gave the company an "outperform" rating in a research report on Friday, July 24th. Barclays upped their price target on shares of Medpace from $625.00 to $675.00 and gave the stock an "equal weight" rating in a report on Friday, October 23rd. Finally, Leerink Partners set a $620.00 price target on shares of Medpace in a research report on Thursday, July 23rd.
Get Our Latest Stock Analysis on Medpace
Insider Activity at Medpace
In other Medpace news, CEO August Troendle sold 49,018 shares of the company's stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the completion of the sale, the chief executive officer directly owned 433,372 shares in the company, valued at $272,205,286.92. This represents a 10.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Susan Burwig sold 16,060 shares of the firm's stock in a transaction on Monday, October 26th. The shares were sold at an average price of $677.00, for a total value of $10,872,620.00. Following the completion of the sale, the vice president directly owned 57,624 shares in the company, valued at approximately $39,011,448. This represents a 21.80% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 278,647 shares of company stock valued at $174,850,299. Company insiders own 20.50% of the company's stock.
Institutional Trading of Medpace
Several institutional investors and hedge funds have recently modified their holdings of MEDP. Virtu Financial LLC bought a new position in shares of Medpace in the 3rd quarter worth about $960,000. Allworth Financial LP boosted its position in shares of Medpace by 8.9% during the 3rd quarter. Allworth Financial LP now owns 4,242 shares of the company's stock valued at $2,648,000 after purchasing an additional 348 shares in the last quarter. Aquatic Capital Management LLC bought a new stake in shares of Medpace during the 3rd quarter valued at about $8,238,000. Worldquant Millennium Advisors LLC bought a new stake in shares of Medpace during the 3rd quarter valued at about $19,574,000. Finally, Toronto Dominion Bank boosted its position in shares of Medpace by 2,193.6% during the 3rd quarter. Toronto Dominion Bank now owns 13,188 shares of the company's stock valued at $8,231,000 after purchasing an additional 12,613 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.
Medpace Stock Performance
MEDP opened at $653.09 on Wednesday. The firm has a market cap of $18.27 billion, a P/E ratio of 36.20, a price-to-earnings-growth ratio of 2.52 and a beta of 1.12. Medpace has a 52-week low of $373.00 and a 52-week high of $693.97. The business's fifty day moving average is $631.90 and its 200-day moving average is $534.34.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, topping analysts' consensus estimates of $4.44 by $0.40. The company had revenue of $716.00 million for the quarter, compared to analysts' expectations of $714.47 million. Medpace had a return on equity of 99.76% and a net margin of 18.24%. Medpace's revenue was up 8.5% on a year-over-year basis. During the same quarter last year, the business earned $3.86 earnings per share. On average, research analysts predict that Medpace will post 18.06 earnings per share for the current fiscal year.
About Medpace
(
Get Free Report)
Medpace Holdings, Inc. is a global contract research organization (CRO) that provides clinical development services to the biotechnology, pharmaceutical and medical device industries. Founded in 1992 and headquartered in Cincinnati, Ohio, the company works with clients developing treatments and medical products across a range of therapeutic areas. Medpace offers services spanning the clinical development process, including clinical trial planning and management, regulatory affairs, clinical laboratory testing, data management, biostatistics, medical writing and pharmacovigilance.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.